Nektar Therapeutics (NKTR) stock
NKTRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$35.91−0.53 (-1.45%)
Close on Nov 17, 2026Market cap $1.23BP/E –Yield –
Nektar Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Nektar Therapeutics's operating margin for the twelve months ending Dec 31, 2025 was -253.7%. For fiscal 2025 it was -253.7%, against -106.9% the year before. The highest annual figure on record is 57.6% in fiscal 2018.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -253.7% | −146.8 |
| FY2024 | Dec 31, 2024 | -106.9% | +185.7 |
| FY2023 | Dec 31, 2023 | -292.6% | +116.0 |
| FY2022 | Dec 31, 2022 | -408.6% | +29.1 |
| FY2021 | Dec 31, 2021 | -437.8% | −159.8 |
| FY2020 | Dec 31, 2020 | -278.0% | +105.9 |
| FY2019 | Dec 31, 2019 | -383.9% | −441.6 |
| FY2018 | Dec 31, 2018 | 57.6% | +77.0 |
| FY2017 | Dec 31, 2017 | -19.4% | +48.8 |
| FY2016 | Dec 31, 2016 | -68.2% | −55.5 |
| FY2015 | Dec 31, 2015 | -12.7% | −4.5 |
| FY2014 | Dec 31, 2014 | -8.2% | +72.5 |
| FY2013 | Dec 31, 2013 | -80.7% | +93.2 |
| FY2012 | Dec 31, 2012 | -173.9% | −0.5 |
| FY2011 | Dec 31, 2011 | -173.4% | −155.6 |
| FY2010 | Dec 31, 2010 | -17.8% | +114.5 |
| FY2009 | Dec 31, 2009 | -132.3% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | -126.9% | −176.0 |
| Q3 FY2025 | Sep 30, 2025 | -268.6% | −126.3 |
| Q2 FY2025 | Jun 30, 2025 | -324.2% | −112.3 |
| Q1 FY2025 | Mar 31, 2025 | -425.8% | −262.0 |
| Q4 FY2024 | Dec 31, 2024 | 49.2% | +189.5 |
| Q3 FY2024 | Sep 30, 2024 | -142.4% | +43.4 |
| Q2 FY2024 | Jun 30, 2024 | -211.9% | +34.9 |
| Q1 FY2024 | Mar 31, 2024 | -163.7% | +460.1 |
| Q4 FY2023 | Dec 31, 2023 | -140.3% | +97.9 |
| Q3 FY2023 | Sep 30, 2023 | -185.8% | +44.0 |
| Q2 FY2023 | Jun 30, 2023 | -246.8% | +461.2 |
| Q1 FY2023 | Mar 31, 2023 | -623.8% | −154.2 |
| Q4 FY2022 | Dec 31, 2022 | -238.2% | +213.2 |
| Q3 FY2022 | Sep 30, 2022 | -229.8% | +226.0 |
| Q2 FY2022 | Jun 30, 2022 | -708.1% | −319.1 |
| Q1 FY2022 | Mar 31, 2022 | -469.6% | −7.0 |
| Q4 FY2021 | Dec 31, 2021 | -451.5% | +20.4 |
| Q3 FY2021 | Sep 30, 2021 | -455.8% | −112.7 |
| Q2 FY2021 | Jun 30, 2021 | -389.0% | −229.9 |
| Q1 FY2021 | Mar 31, 2021 | -462.6% | −198.4 |
| Q4 FY2020 | Dec 31, 2020 | -471.9% | −148.1 |
| Q3 FY2020 | Sep 30, 2020 | -343.1% | −5.2 |
| Q2 FY2020 | Jun 30, 2020 | -159.1% | +316.9 |
| Q1 FY2020 | Mar 31, 2020 | -264.2% | +163.4 |
| Q4 FY2019 | Dec 31, 2019 | -323.8% | −71.9 |
| Q3 FY2019 | Sep 30, 2019 | -337.9% | +17.3 |
| Q2 FY2019 | Jun 30, 2019 | -476.0% | −565.5 |
| Q1 FY2019 | Mar 31, 2019 | -427.6% | −199.5 |
| Q4 FY2018 | Dec 31, 2018 | -251.8% | −226.7 |
| Q3 FY2018 | Sep 30, 2018 | -355.3% | −400.7 |
| Q2 FY2018 | Jun 30, 2018 | 89.5% | +236.0 |
| Q1 FY2018 | Mar 31, 2018 | -228.2% | −8.0 |
| Q4 FY2017 | Dec 31, 2017 | -25.2% | +60.7 |
| Q3 FY2017 | Sep 30, 2017 | 45.4% | +136.0 |
| Q2 FY2017 | Jun 30, 2017 | -146.5% | −29.5 |
| Q1 FY2017 | Mar 31, 2017 | -220.1% | – |
| Q4 FY2016 | Dec 31, 2016 | -85.8% | – |
| Q3 FY2016 | Sep 30, 2016 | -90.5% | – |
| Q2 FY2016 | Jun 30, 2016 | -117.0% | – |
See a number that looks wrong?